Search Results
Your search for ,maY matches 16474 pages
Showing 4251 - 4300Oncology Care Remains Under Strain in the Ongoing COVID-19 Pandemic
The resurging COVID-19 pandemic has reawakened challenges for patients and physicians—ones we all hoped were over—and presented stressful situations for patients and providers. Hospitals in some states, particularly those with lower vaccination rates, have faced levels of urgent illness that have...
Expert Point of View: Ichiro Yoshino, MD, PhD
Ichiro Yoshino, MD, PhD, Professor and Chairman of the Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Japan, reviewed the finer details of the IMpower010 exploratory analysis.1 He maintained that atezolizumab’s benefit does, indeed, seem to favor some patient...
IMpower010: Benefits Observed With Atezolizumab Regardless of Stage, Type of Prior Treatment
In an exploratory analysis of the pivotal phase III IMpower010 trial in stage II–IIIA non–small cell lung cancer (NSCLC), continued treatment with the monoclonal antibody atezolizumab after surgery and chemotherapy improved disease-free survival regardless of the type of surgery or chemotherapy...
Expert Point of View: Shanu Modi, MD
Shanu Modi, MD, of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York, called the DESTINY-Breast03 results,1 which showed a highly significant benefit for fam-trastuzumab deruxtecan-nxki (T-DXd) over trastuzumab emtansine (T-DM1), “unprecedented.” She suggested they...
DESTINY Breast03 Trial Supports Second-Line Use of T-DXd in Metastatic HER2-Positive Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) may become a new option as a second-line treatment of patients with HER2-positive unresectable or metastatic breast cancer, based on results from the global phase III DESTINY-Breast03 trial. These findings were presented by Javier...
FDA Pipeline: Recent Reviews, Designations, Applications, and Authorizations in the Oncology Space
Over the past month, the U.S. Food and Drug Administration (FDA) issued several regulatory decisions for novel treatments for patients with cancer. Priority Review for Relatlimab and Nivolumab Fixed-Dose Combination in Unresectable or Metastatic Melanoma The FDA accepted for Priority Review the...
Effect of Chronic Stress on Treatment Completion and Survival Outcomes in Patients With Breast Cancer
Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node–positive or high-risk lymph node–negative HER2-negative breast cancer, according to results presented by Samilia Obeng-Gyasi, MD, MPH, at the 14th ...
ARAMIS Analysis: Darolutamide Shows Similar Benefits for Black Patients as Observed in the Overall Population
Black patients with prostate cancer who were treated with the androgen receptor inhibitor darolutamide had clinical outcomes similar to those observed in the overall clinical trial population, according to results from the phase III ARAMIS trial presented by Neal Shore, MD, at the 14th AACR...
Study Finds Significant Variation in the Incidence of Nasopharyngeal Cancer Among Ethnic Subgroups of Asian Americans
Although nasopharyngeal cancer is quite rare in most parts of the world, including the United States, the cancer causes a significant health burden among Asian Americans, which is a fast-growing but understudied racial group. According to the results from a study by Lee et al presented at the...
Rates of Diagnosis of Gastrointestinal Cancers—and Stage at Diagnosis—Before and During the COVID-19 Pandemic in Japan
In a study reported in JAMA Network Open, Kuzuu et al found that the COVID-19 pandemic in Japan was associated with reduced rates of new diagnoses, as well as reduced rates of diagnosis at earlier stages, for some gastrointestinal cancers. Study Details The retrospective cohort study included data...
PALB2 Added to Secondary Findings List
“It is important to note that a paper on managing individuals with germline variants in PALB2 was published in the same issue of Genetics in Medicine as an article on reporting secondary findings in clinical exome and genome sequencing,”1,2 Douglas R. Stewart, MD, told The ASCO Post. “PALB2 is a...
Enhanced Surveillance and Risk-Reducing Intervention Options for Individuals With PALB2 Variants
PALB2 germline pathogenic variants are associated with a substantially increased risk for breast cancer and a smaller increased risk for pancreatic and ovarian cancers, warranting enhanced surveillance and the option of risk-reducing interventions, according to a global team of cancer genetic...
Overcoming the Stigma of Small Cell Lung Cancer
Since my small cell lung cancer diagnosis in 2010, I’ve had to overcome not just the distress of having a life-threatening disease, but the stigma attached to it as well. I admit that I was a smoker. I was attracted to smoking when I was 16 and saw how “cool” people looked smoking in television and ...
A Guide to End-of-Life Care by a Veteran in Hospice
Given that death is a certain outcome in life, we seek the best way out as possible. What is a good death? According to Jeff Spiess, MD, author of the book Dying With Ease: A Compassionate Guide to Making Wiser End-of-Life Decisions, a good death is one in which pain and suffering are minimized and ...
Divya A. Parikh, MD, on Improving Care Documentation With a Patient Conversation Guide
Divya A. Parikh, MD, of Stanford University School of Medicine, discusses findings that suggest an evidence-based tool, the Serious Illness Conversation Guide, may engage patients with metastatic or recurrent urologic cancer in goals-of-care conversations, potentially resulting in an increase of...
Glancing Back and Looking Forward in the Fight Against Cancer
“I vividly remember watching television with my older sister, Suzy, and marveling at President Nixon’s signing of the National Cancer Act in December 1971, and thinking ‘for me, this was like a man going to the moon,’” writes Nancy G. Brinker in the foreword to the recently published Centers of the ...
How ASCO Is Expanding Its Commitment to Diversity and Equity in Cancer Care
Ensuring equitable cancer care for every patient, everywhere has been embedded into ASCO’s mission statement since the Society’s inception nearly 60 years ago. Nevertheless, events of the past year, including the ongoing COVID-19 pandemic, which has disproportionally impacted minority communities, ...
Study Finds Some Pancreatic Cancer Trial Eligibility Criteria Disproportionately Exclude Black Patients
Although lack of clinical trial participation is associated with worse survival outcomes in some malignancies, data show that Black patients with cancer represent just 7.3% of participants—and only 4.5% for such cancers as multiple myeloma—in cancer clinical trials, compared with 84.2% for White...
Study Finds Medicaid Expansion May Be Associated With Decrease in Early Lung Cancer Mortality
Medicare expansion under the Affordable Care Act may have improved outcomes for patients with lung cancer, the leading cause of cancer death in the United States, according to data presented at the 2021 ASCO Quality Care Symposium.1 The National Cancer Database analysis of nearly 12,000 patients...
Resurgence of COVID-19 Infection in a Large Highly Vaccinated U.S. Health System Workforce
In a letter to the editor in The New England Journal of Medicine, Jocelyn Keehner, MD, of the University of California San Diego Health (UCSDH), and colleagues describe a marked resurgence of COVID-19 infections among fully vaccinated workers in the UCSDH workforce in July 2021.1 The resurgence...
Antibody Response to COVID-19 Vaccination in Patients With Hematologic or Solid Cancers
In a study reported in JAMA Oncology, Mair et al found that antibody response to COVID-19 vaccination was poorer in patients with hematologic or solid malignancies compared with health-care workers. The investigators also identified factors associated with poorer antibody response among patients....
Courtney Williams, DrPH, on Cancer Survivors: Working Together to Improve Patient Adherence
Courtney Williams, DrPH, of the National Cancer Institute, discusses the costs associated with cancer survivors who don’t take their medications and cites the need for research to better understand whether residing in an urban or rural area may affect prescription adherence, and what interventions...
Jyoti Patel, MD, Offers Thoughts on Maintenance Durvalumab Utilization
Study discussant Jyoti Patel, MD, Medical Director of Thoracic Oncology and Assistant Director for Clinical Research at the Lurie Cancer Center of Northwestern University, Chicago, called the research “important for many reasons.” Although the study analyzed data from both open and closed claims,...
Maintenance Durvalumab: Increased Utilization May Improve Outcomes in NSCLC
Maintenance durvalumab, the standard-of-care treatment for patients with unresectable stage III non–small cell lung cancer (NSCLC), remains significantly underutilized, according to data presented at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung...
Tackling a Growing Need: Options After CAR T-Cell Therapy for Lymphoma
For aggressive B-cell lymphomas, chimeric antigen receptor (CAR) T-cell therapy saves lives, but relapse remains common, and a second-line standard of care is lacking. During the 2021 Pan Pacific Lymphoma Conference, Grzegorz (Greg) S. Nowakowski, MD, Professor of Medicine and Oncology, Lymphoma...
Study Examines Benefits of Cervical Cancer Screening Program Tailored to Transgender Men and Nonbinary People
Worldwide, cervical cancer is the fifth most commonly occurring cancer in women, mostly due to human papillomavirus (HPV) infection. In 2020, globally, an estimated 604,237 women were diagnosed with cervical cancer and about 341,843 died from the disease. In the United States, in 2021, it is...
Black Patients With Advanced NSCLC Receiving Immunotherapy May Have a Lower Risk of Death Than White Patients
Collectively, Black Americans have the highest death rate and shortest survival of any racial/ethnic group in the United States for most cancers; Black men also have the highest cancer incidence rate. Despite improvements in survival disparities between Black and White Americans in specific cancers ...
Addition of Ramucirumab or Merestinib to First-Line Chemotherapy in Advanced Biliary Tract Cancer
In a phase II trial reported in The Lancet Oncology, Juan W. Valle, MD, and colleagues found that no progression-free survival benefit was achieved with the addition of either the VEGFR2 inhibitor ramucirumab or the MEK inhibitor merestinib to first-line cisplatin/gemcitabine chemotherapy in...
Factors Associated With Risk of Hearing Loss in Pediatric Patients Receiving Radiation and Chemotherapy
In a single-institution cohort study reported in the Journal of Clinical Oncology, Keilty et al identified factors associated with an increased risk of hearing loss in pediatric patients receiving radiation therapy and chemotherapy for central nervous system and head and neck tumors. The study...
Adding Value to Clinical Decision-Making in Nonmetastatic Castration-Resistant Prostate Cancer
Several recent investigations have led to the U.S. Food and Drug Administration (FDA) approval of novel antiandrogens to treat nonmetastatic castration-resistant prostate cancer. Yet, this work has not addressed the treatment of nonmetastatic hormone-sensitive biochemically recurrent prostate...
Rates of Postprotocol Immunotherapy Use in Patients Enrolled in Kidney Cancer Clinical Trials
In an analysis reported in JAMA Network Open, Sharp et al identified the frequency of use of postprotocol PD-1/PD-L1 inhibitors in control group patients receiving the tyrosine kinase inhibitor sunitinib in randomized trials comparing PD-1/PD-L1 inhibitor–containing combination therapy vs sunitinib ...
Does a Longer Interval Before Surgery Among Patients With Locally Advanced Rectal Cancer Lead to Worse Survival?
In an Italian retrospective cohort study reported in JAMA Surgery, Deidda et al found that a longer vs shorter delay to surgery among patients with locally advanced rectal cancer with minor or no pathologic response to neoadjuvant chemoradiotherapy was associated with significantly poorer overall...
Trends in Use of Neoadjuvant Chemotherapy and Association With Overall Survival in Patients With Advanced Ovarian Cancer
In a study reported in JAMA Oncology, Alexander Melamed, MD, MPH, and colleagues found that improvements in median overall survival have been similar in patients from U.S. cancer programs that did vs did not increase their use of neoadjuvant chemotherapy for women with advanced ovarian cancer in...
Axicabtagene Ciloleucel for Adult Patients With Primary Mediastinal B-Cell Lymphoma: Real-World Outcomes
In a retrospective cohort study reported in a research letter in Blood Advances, Jennifer L. Crombie, MD, and colleagues found that axicabtagene ciloleucel produced high overall and complete response rates in patients with primary mediastinal B-cell lymphoma. They also observed some evidence to...
Two Studies Show Health-Care Costs May Impact Follow-up Care After Cancer Screening
Eleven years ago this month, the scans and exams that hold the most power to spot the early signs of cancer became available for free to many American adults through the passing of the Affordable Care Act. Now, two new studies show that when those screening tests reveal potentially troubling signs, ...
Improved Health Insurance Coverage, Access to Care May Lessen Racial/Ethnic Disparities in Childhood Cancer Survival
A new study published by Jingxuan Zhao, MPH, and colleagues in Cancer Epidemiology, Biomarkers & Prevention found racial/ethnic disparities in survival among newly diagnosed patients with childhood cancers in the United States, and that area-level socioeconomic status and health insurance...
Radioembolization Plus Second-Line Chemotherapy for Colorectal Liver Metastases
In the phase III EPOCH trial reported in the Journal of Clinical Oncology, Mary F. Mulcahy, MD, and colleagues found that the addition of transarterial yttrium-90 radioembolization (TARE) to second-line chemotherapy significantly prolonged progression-free survival and hepatic progression–free...
Ivosidenib vs Placebo for Previously Treated Advanced IDH1-Mutated Cholangiocarcinoma: Final Overall Survival Analysis of the ClarIDHy Trial
As reported in JAMA Oncology by Andrew X. Zhu, MD, PhD, and colleagues, the final overall survival analysis of the pivotal phase III ClarIDHy trial showed prolonged overall survival with ivosidenib vs placebo in previously treated patients with unresectable or metastatic cholangiocarcinoma and an...
Addition of Panitumumab to Fluorouracil/Leucovorin as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer
In the German phase II PANAMA trial reported in the Journal of Clinical Oncology, Modest et al found that the addition of the monoclonal antibody panitumumab to fluorouracil (5-FU)/leucovorin maintenance therapy improved progression-free survival in patients with RAS wild-type metastatic colorectal ...
Luis E. Aguirre, MD, on Chronic Myelomonocytic Leukemia: Keys to Assessment and Treatment
Luis E. Aguirre, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses the subset of patients with chronic myelomonocytic leukemia who have a more indolent disease course. Features at diagnosis may include higher hemoglobin and platelet counts or JAK2, SF3B1, and IDH2 mutations; ...
Biomarker May Help to Predict Response to Gemcitabine for Patients With High-Grade Serous Ovarian Cancer
For more than 2 decades, the chemotherapy agent gemcitabine has been a mainstay treatment for several types of cancer. Now, scientists have uncovered genetic evidence of which patients with high-grade serous ovarian cancer are likely to benefit from the drug. In a study published by Panagiotis...
Study Finds Genetic Predisposition to Higher Lymphocyte Production May Lead to Higher ALL Risk
Research published by Kachuri et al in the American Journal of Human Genetics reveals that children born with a genetic predisposition to produce more lymphocytes—particularly in relation to other types of white blood cells—may be at a higher risk of developing acute lymphoblastic leukemia (ALL)....
Effectiveness of mRNA COVID-19 Vaccination in Preventing Symptomatic Infection in Health-Care Personnel
As reported in The New England Journal of Medicine by Pilishvili et al for the Vaccine Effectiveness among Healthcare Personnel Study Team, a case-control study has shown that full vaccination with the COVID-19 mRNA vaccines was highly effective in preventing symptomatic COVID-19 infection in U.S....
Liver Biopsy for Evaluation of Hepatitis Associated With Immunotherapy
In a retrospective cohort study reported in a research letter in JAMA Oncology, Li et al found that the performance of liver biopsy in patients with grade ≥ 3 alanine aminotransferase (ALT) elevations during immune checkpoint inhibitor therapy was associated with a delayed start of corticosteroid...
Triplet Therapy and Lenalidomide Maintenance to Prevent Disease Progression in High-Risk Smoldering Myeloma
In a single-center phase II trial reported in JAMA Oncology, Kazandjian et al found that triplet therapy with carfilzomib, lenalidomide, and dexamethasone (KRd), followed by lenalidomide maintenance, produced high rates of measurable residual disease (MRD)-negative complete response and freedom...
Poziotinib, a Tyrosine Kinase Inhibitor, for HER2 Exon 20–Mutant NSCLC
In a single-center phase II trial reported in the Journal of Clinical Oncology, Elamin et al found that the tyrosine kinase inhibitor poziotinib showed activity in previously treated patients with HER2 exon 20–mutant advanced non–small cell lung cancer (NSCLC). As related by the investigators,...
CASSIOPEIA Part 2: Maintenance Daratumumab After Initial Therapy for Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Philippe Moreau, MD, and colleagues, an interim analysis of part 2 of the phase III CASSIOPEIA trial has shown significantly prolonged progression-free survival with maintenance daratumumab vs observation following induction and consolidation with or without...
Classifying EGFR Mutations by Structure and Function May Help to Match Patients With NSCLC to More Effective Treatments
Researchers have discovered that grouping EGFR mutations by structure and function provides an accurate framework to match patients with non–small cell lung cancer (NSCLC) to the right drugs. The findings, published by Robichaux et al in Nature, identify four subgroups of mutations and introduce a...
Tina Shih, PhD, on Trends in Total and Out-of-Pocket Costs of Cancer Care
Tina Shih, PhD, of The University of Texas MD Anderson Cancer Center, discusses the rising cost-sharing requirement from private insurance, which has worsened the financial burden for patients with cancer. She believes that cost-containment policies alone may not be enough to ease this hardship.
Are Rates of Hepatocellular Carcinoma Rising in Rural Areas of the United States?
Historically, rates of hepatocellular carcinoma (HCC) have been lower in rural areas than urban regions. However, a recent study published by Zhou et al in Clinical Gastroenterology and Hepatology shows that while cases of HCC have begun slowing in urban communities in the United States, the...
